文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

SCREEN-ROP标准用于早产儿视网膜病变筛查的验证:一个可供参考的加拿大模型

Validation of the SCREENROP Criteria for Retinopathy of Prematurity Screening: A Canadian Model for Consideration.
PubMed 文献 · Am J Ophthalmol · 2025-04-16

该研究在加拿大McMaster儿童医院回顾性分析了2016年7月1日至2024年5月31日接受至少一次ROP检查或治疗的823名婴儿,验证SCREEN-ROP标准(出生体重<1200 g或胎龄<30周)的筛查敏感性。结果显示该标准捕获了全部79名需治疗ROP的婴儿,敏感性100%(95%CI:95.44%至100%),特异性8.20%(95%CI:6.33%至10.41%),并使61名婴儿(7.41%)免于不必要的筛查。作者认为需在其他大型中心和国家进一步验证以推广该指南。

要点

  • SCREEN-ROP标准(出生体重<1200 g或胎龄<30周)在823名婴儿中捕获全部79名需治疗ROP者,敏感性100%(95%CI:95.44%至100%)。
  • 应用该标准可使61名婴儿(7.41%)免于不必要的ROP筛查,特异性为8.20%(95%CI:6.33%至10.41%)。
  • 作者结论指出需在其他大型中心和国家进一步验证,才可能更广泛实施SCREEN-ROP指南。

核心结论

  • 采用出生体重<1200 g或胎龄<30周的SCREEN-ROP标准,可使7.41%的婴儿免于不必要的ROP筛查,并以100%敏感性捕获全部需治疗ROP的婴儿。
  • 需在其他大型中心和国家进一步验证,才可能更广泛实施SCREEN-ROP指南。

研究设计与样本

  • 回顾性准确性分析,评估修订后的诊断检测标准。
  • 纳入2016年7月1日至2024年5月31日在McMaster儿童医院出生且接受至少一次ROP眼科检查或ROP治疗的婴儿。
  • 出生体重和胎龄数据分别来自加拿大新生儿网络(CNN)和BORN Ontario,后者存储所有入住3级和2级新生儿重症监护室婴儿的信息。
  • 共筛查823名独特婴儿,其中79名独特婴儿因ROP接受治疗。
  • 研究获Hamilton整合研究伦理委员会(REB #13216-C)和CNN(REB #04-062)机构伦理批准。

主要发现

  • 应用SCREEN-ROP标准捕获了全部79名需ROP治疗的婴儿。
  • 应用SCREEN-ROP标准使另外61名婴儿(7.41%)免于被不必要地纳入ROP筛查。
  • SCREEN-ROP标准捕获需ROP治疗婴儿的敏感性为100%(95%CI:95.44%至100%),特异性为8.20%(95%CI:6.33%至10.41%)。
  • 使用卡方检验比较SCREEN-ROP标准与先前标准(胎龄<31周或出生体重<1251 g)所捕获的婴儿。

关键数值与推荐

  • SCREEN-ROP指南推荐仅筛查出生体重<1200 g或胎龄<30周的婴儿,以避免不必要的筛查。
  • SCREEN-ROP标准的敏感性为100%(95%CI:95.44%至100%),特异性为8.20%(95%CI:6.33%至10.41%)。
  • 应用SCREEN-ROP标准可使61名婴儿(7.41%)免于不必要的ROP筛查。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需在其他大型中心和国家进一步验证,才可能更广泛实施SCREEN-ROP指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Reducing unnecessary retinopathy of prematurity (ROP) screenings in neonates is important for minimizing morbidity associated with such examinations including pain for the child, anxiety in parents, and conserving healthcare resources. The Seminal Canadian Recommendations for Evidence-Based Examination of Neonates for Retinopathy of Prematurity (SCREEN-ROP) guidelines recommend only screening babies with birth weight (BW) <1200 g or gestational age (GA) <30 weeks to prevent unnecessary screenings. This study aims to retrospectively test the sensitivity of SCREEN-ROP in a large urban Canadian setting for capturing babies requiring treatment for ROP. DESIGN: Retrospective accuracy analysis of revised diagnostic testing criteria. METHODS: All babies born at McMaster Children Hospital from July 1, 2016 to May 31, 2024 who: 1) received at least one ROP eye exam, or 2) received ROP treatment, were included. Birth weight (BW) and gestational age (GA) at birth were collected from Canadian Neonatal Network (CNN) and BORN Ontario, which stores all information on babies admitted to level 3 and level 2 Neonatal Intensive Care Units (NICUs), respectively. SCREEN-ROP criteria were applied to the cohort. Institutional ethics approval was obtained from Hamilton Integrated Research Ethics Board (REB #13216-C) and CNN (REB #04-062). RESULTS: Sensitivity and specificity of the model was calculated with 95% confidence intervals. Chi-squarede test was used to compare the babies captured with SCREEN-ROP criteria versus prior criteria (GA<31 weeks or birth weight <1251 g). 823 unique babies were screened from July 1, 2016 to May 31, 2024 of which 79 unique babies were treated for ROP. Applying the SCREEN-ROP criteria captured all 79 babies requiring ROP treatment while avoiding another 61 babies (7.41%) from being unnecessarily enrolled into ROP screening. Sensitivity of SCREEN-ROP criteria for capturing babies requiring ROP treatment was 100% (95% CI: 95.44% to 100%), and the specificity was 8.20% (95% CI: 6.33% to 10.41%). CONCLUSIONS: By screening babies with BW <1200 g or GA <30 weeks, 7.41% of babies would have been saved from unnecessary ROP screenings, and all babies requiring ROP treatment would have been captured with 100% sensitivity. Further validation in other large centers and countries may allow for broader implementation of SCREEN-ROP guidelines.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Tai F, Jindani Y, Mukerji A, et al. Validation of the SCREENROP Criteria for Retinopathy of Prematurity Screening: A Canadian Model for Consideration. Am J Ophthalmol. 2025. PMID: 40250745. doi:10.1016/j.ajo.2025.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。